miRNAs significantly different in SER samples from PD vs. PDD and Control vs. AD.

Sample size for serum consisted of PD (n = 322), PDD (n = 188), AD (n = 53) and Control (n = 62) subjects. Results were filtered at corrected p-value <0.05. The logarithmic base 2 fold change (FC) is

NIAID Data Ecosystem10

Dementia Comparison: VaD vs. AD vs. Controls. Dementia Comparison: VaD vs. AD vs. Controls

Gene expression profiling was performed on frontal and temporal cortex from vascular dementia (VaD), Alzheimer's disease (AD), and non-demented controls (Control) obtained from the University of Michi

NIAID Data Ecosystem10

Identification of differentially expressed miRNAs in PD vs. nonPD in cancer samples

Lack of a standard method for stratifying advanced-stage NSCLC patients receiving platinum combination therapy often results in a number of patients that do not derive benefit yet are still exposed to

NIAID Data Ecosystem20